600 patients66,869 observations120 daysLIVE

Patient P-01356

Synthetic patientNBL-101 · Day 116 · 45–54 · F · baseline S14Open companion preview
Therapy response
Unstable
Tolerance
Improving
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 49 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 52 SC-12 recommendedSupportive Compound SC-12
  4. Day 53 Patient acceptedStarted SC-12 in the companion
  5. Day 59 No meaningful changeSupportive Compound SC-12
  6. Day 60 GI-04 recommendedGI Support Protocol GI-04
  7. Day 61 Patient acceptedStarted GI-04 in the companion
  8. Day 69 GI symptom burden −21% vs expectedGI Support Protocol GI-04
  9. Day 75 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • Toxicity-11
  • Nutritional resilience-7
  • GI instability+4
  • Treatment adherence-4

What helped?

  • Supportive Compound SC-12Day 52
    Result: no meaningful change
  • GI Support Protocol GI-04Day 60
    Result: symptom burden −21%
LIFE OS recommendation
Dietary Support Protocol NP-02
59%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 48 and rising
    • WearableSleep 5.7 h, below personal baseline
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 24/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 47
  • Autonomic recovery 40
    • Wearable2,806 steps/day
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 24/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
55 ms
Sleep
5.9 h
Steps
2,783
Resting HR
70 bpm
Daily log: GI score 48, nutritional resilience 39, adherence 48.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0138960%S14SC-12improved46
P-0150556%S14NP-02improved41
P-0145855%S14GI-04improved44
P-0136553%S14SC-12improved49
P-0141353%S14GI-04improved44
P-0178153%S14NP-02improved45
P-0143652%S14GI-04improved38
P-0155952%S06GI-04improved42
P-0130751%S14GI-04improved43
P-0155650%S14GI-04improved44
P-0161650%S14GI-04improved39
P-0148649%S18GI-04improved47